Deerfield Discovery and Development (3DC)
Deerfield’s internal research and development engine, 3DC, seeks to advance early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic for the benefit of patients.
3DC is a company-building R&D engine.
Deerfield Discovery and Development (3DC) is a partner to various stakeholders in the biotech ecosystem, including principal investigators in Deerfield’s academic collaboration network, startups, and biopharma companies.
Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide.
3DC is led by Chief Executive Officer Frank Nestle, MD.
Deeply experienced drug hunters seek to advance a competitive portfolio of high-impact medicines
Working with Entrepreneurs
3DC offers turnkey drug discovery expertise and capabilities to founders to advance the therapeutic development of small molecules and biologics.
Instead of building an R&D team from scratch, Deerfield-backed startups can leverage 3DC to advance development plans faster and in collaboration with seasoned biotech and pharma veterans on staff.
Partnering with Biopharma
Deerfield’s infrastructure can support the development of compelling assets on behalf of or in partnership with strategics and corporate partners.
Our team can acquire, transform, mature, and integrate development-stage and commercial assets prior to or in preparation for a corporate acquisition.
.jpg)
Laboratory Space at Cure
3DC scientists enjoy access to in-building laboratory facilities including state-of-the-art equipment like cryo-EM, NMR, flow cytometry, automated screening robots, and high-throughput mass spectrometry.
Deerfield partners with leading academic research centers, aiming to provide critical funding and expertise to sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
In June 2023, NYU Langone Health and Deerfield Management Company announced the launch of a research and development collaboration designed to accelerate the commercialization of biomedical discoveries.
In September 2022, Moffitt Cancer Center, one of the nation’s leading cancer care and research institutions, and Deerfield Management announced a translational research alliance through a newly launched company called Bayfield Therapeutics LLC, to accelerate the development of new therapeutics to treat cancer. Deerfield has committed up to $130 million over the next 10 years to this collaboration.
In April 2021, Deerfield and Empire Discovery Institute formed a translational research partnership to accelerate the development of novel therapeutics. The company called Empire Deerfield Discovery and Development expects to translate scientific discoveries with potential applications for patients.
In January 2024, Washington University in St. Louis and Deerfield Management announced the launch of VeritaScience, a private R&D collaboration designed to advance the discovery, clinical development and commercialization of promising therapeutic and diagnostic candidates with potential to benefit human health.
In February 2021, Deerfield and Dana-Farber Cancer Institute announced the formation of a major translational research partnership, Riverway Discoveries. Riverway Discoveries plans to help accelerate the development of therapeutics and diagnostics for cancer.
In October 2018, Deerfield and the University of North Carolina at Chapel Hill announced the launch of Pinnacle Hill, LLC, a Deerfield company seeking to discover new medicines to address the significant unmet medical needs of our times.